SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
GUTS reported Third Quarter 2026 results. The price and volatility reaction is pending.
GUTSearnings

Earnings reactions, page 3

Fractyl Health, Inc. (GUTS) Q3 FY2026 earnings

November 13, 2026 · SharpeIQ Research Desk

Reported results

  • GAAP research and development expenses were $12.5 million for the quarter ended September 30, 2026.
  • GAAP selling, general and administrative expenses were $6.2 million for the quarter ended September 30, 2026.
  • GAAP net loss was $14.2 million for the quarter ended September 30, 2026.
  • Non-GAAP Adjusted EBITDA was negative $16.0 million for the quarter ended September 30, 2026.
  • As of September 30, 2026, the company had $31.5 million in cash and cash equivalents.

Guidance

  • Quarterly operating cash spending expected to be reduced to approximately $8 million by the end of Q2 2027.
  • Cash runway into Q2 2027.

Notes

All share and per share information has been retroactively adjusted to reflect the 1-for-12 reverse stock split effected on October 2, 2026.

Price and volatility reaction

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-12 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →